Aardvark Therapeutics (AARD) Research & Development (2024 - 2026)

Aardvark Therapeutics (AARD) has 3 years of Research & Development data on file, last reported at $16.6 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 113.63% year-over-year to $16.6 million; the trailing twelve-month figure through Mar 2026 stood at $57.7 million (up 141.51% YoY), and the FY2025 full-year result was $48.9 million, up 181.84% from the prior year.
• Research & Development improved to $16.6 million in Q1 2026, from $14.3 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $16.6 million in Q1 2026 to a low of $1.2 million in Q1 2024.
• A 3-year average of $9.2 million and a median of $8.1 million in 2024 frame the typical range for Research & Development.
• Peak annual rise in Research & Development reached 542.5% in 2025, while the deepest fall reached 77.36% in 2025.
• Tracing AARD's Research & Development over 3 years: stood at $8.1 million in 2024, then soared by 77.36% to $14.3 million in 2025, then climbed by 15.86% to $16.6 million in 2026.
• Business Quant data shows AARD's Research & Development at $16.6 million in Q1 2026, $14.3 million in Q4 2025, and $13.7 million in Q3 2025.